Abstract
Recent findings indicate that soy isoflavones and their metabolites may play a major role in mitigating post‐menopausal bone loss. Equol, a metabolite of soy isoflavone daidzein produced by intestinal bacteria, has shown some potential but only 30–50% of US population is capable of converting dietary daidzein to equol. There is limited data on the pharmacokinetics of dietary equol and its metabolites. This study was conducted to assess the levels of equol and its conjugates in plasma for a 24h period resulting from oral administration of dietary equol in ovariectomized Sprague Dawley rats. Plasma samples were analyzed for using liquid chromatography‐tandem mass spectrometry. Although the majority of equol metabolites present were glucronidated conjugates (≥99%), there were low levels of sulfated conjugates present, specifically equol monosulfate. Pharmacokinetic parameters for equol monosulfate were: Cmax (21±7 nmol/L), Tmax (2.8±2h), AUC0‐t (237±79 nmol h/L), AUC0‐inf (600±390 nmol h/L), T1/2 (32±24h). Pharmacokinetic parameters for glucronidated equol were: Cmax (10.5±2.9μmol/L), Tmax (0.88±0.75h), AUC0‐t (11±14 μmol h/L), AUC0‐inf (179±14 μmol h/L), and T1/2 (16±3h).Grant Funding Source: NIH
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
